130 related articles for article (PubMed ID: 30733496)
1. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Fernandez-Martinez A; Pascual T; Singh B; Nuciforo P; Rashid NU; Ballman KV; Campbell JD; Hoadley KA; Spears PA; Pare L; Brasó-Maristany F; Chic N; Krop I; Partridge A; Cortés J; Llombart-Cussac A; Prat A; Perou CM; Carey LA
JAMA Oncol; 2023 Apr; 9(4):490-499. PubMed ID: 36602784
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Clin Cancer Res; 2023 Feb; 29(3):532-540. PubMed ID: 36449695
[TBL] [Abstract][Full Text] [Related]
5. Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
Blok EJ; Engels CC; Dekker-Ensink G; Meershoek-Klein Kranenbarg E; Putter H; Smit VTHBM; Liefers GJ; Morden JP; Bliss JM; Coombes RC; Bartlett JMS; Kroep JR; van de Velde CJH; Kuppen PJK
Breast Cancer Res Treat; 2018 Aug; 171(1):65-74. PubMed ID: 29766362
[TBL] [Abstract][Full Text] [Related]
6. The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer.
Çetin K; Kökten Ş; Sarıkamış B; Yıldırım S; Gökçe ON; Barışık NÖ; Kılıç Ü
Breast Cancer Res Treat; 2024 May; 205(1):17-27. PubMed ID: 38273215
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Stanton SE; Disis ML
J Immunother Cancer; 2016; 4():59. PubMed ID: 27777769
[TBL] [Abstract][Full Text] [Related]
8. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
[TBL] [Abstract][Full Text] [Related]
9. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
Lesurf R; Griffith OL; Griffith M; Hundal J; Trani L; Watson MA; Aft R; Ellis MJ; Ota D; Suman VJ; Meric-Bernstam F; Leitch AM; Boughey JC; Unzeitig G; Buzdar AU; Hunt KK; Mardis ER
Ann Oncol; 2017 May; 28(5):1070-1077. PubMed ID: 28453704
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis.
Yu X; Zhang Z; Wang Z; Wu P; Qiu F; Huang J
Clin Transl Oncol; 2016 May; 18(5):497-506. PubMed ID: 26459255
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis.
Xia G; Zhang Z; Jiang Q; Wang H; Wang J
Medicine (Baltimore); 2024 Feb; 103(6):e36810. PubMed ID: 38335394
[TBL] [Abstract][Full Text] [Related]
12. Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype.
Orrù S; Pascariello E; Pes B; Rallo V; Barbara R; Muntoni M; Notari F; Fancello G; Mocci C; Muroni MR; Cossu-Rocca P; Angius A; De Miglio MR
Sci Rep; 2023 Aug; 13(1):12869. PubMed ID: 37553381
[TBL] [Abstract][Full Text] [Related]
13. Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.
Varadan V; Gilmore H; Miskimen KL; Tuck D; Parsai S; Awadallah A; Krop IE; Winer EP; Bossuyt V; Somlo G; Abu-Khalaf MM; Fenton MA; Sikov W; Harris LN
Clin Cancer Res; 2016 Jul; 22(13):3249-59. PubMed ID: 26842237
[TBL] [Abstract][Full Text] [Related]
14. HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Baez-Navarro X; van den Ende NS; Nguyen AH; Sinke R; Westenend P; van Brakel JB; Stobbe C; Westerga J; van Deurzen CHM
Breast Cancer Res; 2024 Mar; 26(1):41. PubMed ID: 38468323
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Erol VB; Goktas Aydin S; Bilici A; Cakir A; Acikgoz O; Olmez OF; Basim P
J Chemother; 2023 Nov; 35(7):662-670. PubMed ID: 37599454
[TBL] [Abstract][Full Text] [Related]
16. A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.
Hamy AS; Bonsang-Kitzis H; Lae M; Moarii M; Sadacca B; Pinheiro A; Galliot M; Abecassis J; Laurent C; Reyal F
PLoS One; 2016; 11(12):e0167397. PubMed ID: 28005906
[TBL] [Abstract][Full Text] [Related]
17. Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics.
Balkenhol MC; Ciompi F; Świderska-Chadaj Ż; van de Loo R; Intezar M; Otte-Höller I; Geijs D; Lotz J; Weiss N; de Bel T; Litjens G; Bult P; van der Laak JA
Breast; 2021 Apr; 56():78-87. PubMed ID: 33640523
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.
Liefaard MC; van der Voort A; van Seijen M; Thijssen B; Sanders J; Vonk S; Mittempergher L; Bhaskaran R; de Munck L; van Leeuwen-Stok AE; Salgado R; Horlings HM; Lips EH; Sonke GS
NPJ Breast Cancer; 2024 Apr; 10(1):29. PubMed ID: 38637568
[TBL] [Abstract][Full Text] [Related]
19. HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category.
Karakas C; Tyburski H; Turner BM; Weiss A; Akkipeddi SMK; Dhakal A; Skinner K; Hicks DG; Zhang H
Hum Pathol; 2023 Dec; 142():34-41. PubMed ID: 37979952
[TBL] [Abstract][Full Text] [Related]
20. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.
Griguolo G; Pascual T; Dieci MV; Guarneri V; Prat A
J Immunother Cancer; 2019 Mar; 7(1):90. PubMed ID: 30922362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]